Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

5.330 -0.040 (-0.74%)

Streaming Delayed Price Updated: 10:37 AM EST, Feb 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	32,493
Open	5.330
Bid (Size)	5.320 (300)
Ask (Size)	5.340 (4,900)
Prev. Close	5.370
Today's Range	5.290 - 5.360
52wk Range	4.320 - 13.08
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Today 3:00 EST

From Alvotech

Via GlobeNewswire

Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg

January 29, 2026

From Alvotech

Via GlobeNewswire

Performance

YTD	+6.6%	+6.6%
1 Month	+6.6%	+6.6%
3 Month	+6.0%	+6.0%
6 Month	-39.9%	-39.9%
1 Year	-56.9%	-56.9%

More News

The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion

January 20, 2026

Via MarketMinute

Bragar Eagel & Squire, P.C. Continues Investigations into Alvotech and Beyond Meat on Behalf of Stockholders and Encourages Investors to Contact the Firm

January 13, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

January 09, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

January 06, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Alvotech announces planned CEO succession and leadership transition

January 06, 2026

From Alvotech

Via GlobeNewswire

ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP

January 05, 2026

From Kirby McInerney LLP

Via Business Wire

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

January 01, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Alvotech Secures Term Loan Facility of USD 100 Million

December 31, 2025

From Alvotech

Via GlobeNewswire

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

December 22, 2025

From Alvotech

Via GlobeNewswire

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

December 19, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

December 16, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Continues Investigations into Beyond Meat and Alvotech on Behalf of Stockholders and Encourages Investors to Contact the Firm

December 15, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

December 12, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

December 09, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

December 06, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation – ALVO

December 04, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug ↗

November 24, 2025

Via Stocktwits

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

November 24, 2025

From Alvotech

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Continues Investigations into Regencell, Beyond Meat, Alvotech, and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm

November 22, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

November 20, 2025

From Alvotech

Via GlobeNewswire

ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP

November 19, 2025

From Kirby McInerney LLP

Via Business Wire

Ardent Health, KinderCare Learning, Ibotta And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

November 13, 2025

Via Benzinga

Bragar Eagel & Squire, P.C. Is Investigating Regencell, Beyond Meat, Alvotech, and Camping World and Encourages Investors to Contact the Firm

November 12, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Frequently Asked Questions

Is Alvotech - Ordinary Shares publicly traded?

Yes, Alvotech - Ordinary Shares is publicly traded.

What exchange does Alvotech - Ordinary Shares trade on?

Alvotech - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Alvotech - Ordinary Shares?

The ticker symbol for Alvotech - Ordinary Shares is ALVO on the Nasdaq Stock Market

What is the current price of Alvotech - Ordinary Shares?

The current price of Alvotech - Ordinary Shares is 5.330

When was Alvotech - Ordinary Shares last traded?

The last trade of Alvotech - Ordinary Shares was at 02/02/26 10:37 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.